Is a good buy bcrx now after report?

**BioCryst Pharmaceuticals (BCRX) does not present a strong buying opportunity following the recent earnings report.** Here's why:

1. **Financial Performance**: BCRX reported a quarterly loss of $0.07 per share, which is a significant improvement from the previous year's loss of $0.19 per share. However, this result was in line with the Zacks Consensus Estimate, and the company actually posted a higher revenue than expected, with $117.09 million for the quarter, surpassing the estimate by 2.01%. On the surface, this suggests a positive performance.

2. **Market Reaction and Analyst Ratings**: Despite the earnings beat, BCRX's stock price has experienced a decline, with a 12.81% change as of the latest data point. Analysts have a mixed outlook with a consensus rating of "Moderate Buy" and an average price target of $14.17. This suggests that while there is some positive sentiment, it is not strong enough to indicate a immediate bullish trend.
3. **Future Outlook**: The company's earnings outlook does not provide a clear indication of future growth. The estimate EPS for the next quarter is -$0.06, and the EPS for the current year is projected to be -$0.36. This indicates that the company is expected to continue posting losses, which may be a concern for investors looking for profitability.
4. **Institutional Activity**: There have been some institutional changes, with Rice Hall James & Associates LLC increasing its holdings in BCRX. This could be seen as a positive sign, but it is not indicative of a strong buying momentum.
5. **Stock Performance and Volatility**: BCRX's stock has experienced significant volatility, with a beta of 1.876, which indicates that it is more volatile than the broader market. This could be a factor for investors who are looking for stability.

In conclusion, while BCRX has shown some positive financial performance and has received some institutional support, the mixed analyst ratings, continued losses, and high volatility suggest that it may not be a compelling buy at this time. Investors should exercise caution and consider these factors before making a decision.